Background
Methods
Results
Baseline characteristics and distribution of first primary cancers by cancer type
Study cohort | First primary cancers | Second primary cancers | ||
---|---|---|---|---|
Number of cases | % | Number of cases | % | |
Total | 59,638 | 100 | 4949 | 100 |
Sex | ||||
Males | 31,215 | 52.3 | 3036 | 61.3 |
Females | 28,423 | 47.7 | 1913 | 38.7 |
Age at first diagnosis | ||||
15–24 | 656 | 1.1 | 8 | 0.2 |
25–49 | 9143 | 15.3 | 439 | 8.9 |
50–64 | 19,119 | 32.1 | 1784 | 36.0 |
65–79 | 23,424 | 39.3 | 2356 | 47.6 |
80+ | 7296 | 12.2 | 362 | 7.3 |
Period of first diagnosis | ||||
1988–1990 | 7764 | 13.0 | 706 | 14.3 |
1991–1995 | 15,140 | 25.4 | 1487 | 30.0 |
1996–2000 | 16,837 | 28.2 | 1526 | 30.8 |
2001–2005 | 19,897 | 33.4 | 1230 | 24.9 |
Follow-up interval | ||||
2 months to less than 1 year | 8851 | 14.8 | 546 | 11.0 |
1 year to less than 5 years | 13,279 | 22.3 | 1928 | 39.0 |
5 years to less than 10 years | 17,563 | 29.4 | 1522 | 30.8 |
10 years or longer | 19,945 | 33.4 | 953 | 19.3 |
First primary cancers | Number of cases | % |
---|---|---|
Head/neck/larynx | 2322 | 3.9 |
Stomach | 2974 | 5.0 |
Colon/Rectum | 7138 | 12.0 |
Lung | 5134 | 8.6 |
Breast | 8833 | 14.8 |
Cervix | 1290 | 2.2 |
Endometrium | 1768 | 3.0 |
Ovary | 1310 | 2.2 |
Prostate | 10,103 | 16.9 |
Bladder | 2420 | 4.1 |
Kidney | 1866 | 3.1 |
Thyroid gland | 1088 | 1.8 |
NHL high/low | 1070 | 1.8 |
CLL/ALL | 573 | 1.0 |
Other | 8704 | 14.6 |
Distribution of gender, site and time of occurrence of second primary cancers
Sex | Males | Females | ||
---|---|---|---|---|
First primary cancer | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) |
Head/Neck/Larynx | 281 |
1.88 (1.67–2.11)
| 53 |
1.74 (1.30–2.28)
|
Stomach | 111 | 0.94 (0.77–1.13) | 57 | 0.83 (0.63–1.07) |
Colon/Rectum | 381 | 0.91 (0.82–1.00) | 233 | 0.89 (0.78–1.01) |
Lung | 130 | 0.90 (0.75–1.06) | 56 |
1.58 (1.19–2.05)
|
Melanoma | 133 | 0.93 (0.78–1.10) | 107 | 0.94 (0.77–1.14) |
Breast | 580 |
0.82 (0.75–0.89)
| ||
Cervix | 102 |
1.40 (1.14–1.70)
| ||
Endometrium | 177 | 1.08 (0.92–1.25) | ||
Ovary | 72 | 1.09 (0.85–1.37) | ||
Prostate | 1117 |
0.68 (0.64–0.72)
| ||
Bladder | 300 |
1.20 (1.07–1.34)
| 61 | 1.13 (0.86–1.45) |
Kidney | 162 |
1.22 (1.04–1.42)
| 84 |
1.29 (1.03–1.59)
|
Thyroid gland | 40 | 1.23 (0.88–1.67) | 79 |
1.40 (1.11–1.75)
|
NHL high/low | 68 | 1.20 (0.93–1.53) | 43 | 1.23 (0.89–1.66) |
CLL/ALL | 34 | 0.93 (0.64–1.30) | 22 | 1.11 (0.69–1.67) |
All cancers combined | 3036 |
0.90 (0.86–0.93)
| 1913 | 1.00 (0.96–1.05) |
All cancers except Prostate | 1919 |
1.10 (1.05–1.15)
|
Age at diagnosis of the first primary cancer
Age group at first diagnosis | ||||||
---|---|---|---|---|---|---|
15–49 years | 50–64 years | 65 years and over | ||||
First primary cancer | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) |
Head/Neck/Larynx | 42 |
2.35 (1.69–3.17)
| 189 |
2.21 (1.91–2.55)
| 103 |
1.34 (1.10–1.63)
|
Stomach | 8 | 1.14 (0.49–2.25) | 43 | 0.92 (0.66–1.24) | 117 | 0.88 (0.72–1.05) |
Colon/Rectum | 29 | 1.17 (0.78–1.68) | 200 | 1.03 (0.89–1.18) | 385 |
0.83 (0.75–0.92)
|
Lung | 13 | 1.31 (0.70–2.25) | 83 | 1.13 (0.90–1.40) | 90 | 0.93 (0.74–1.14) |
Melanoma | 54 | 1.18 (0.89–1.54) | 88 | 0.89 (0.71–1.10) | 98 | 0.88 (0.71–1.07) |
Breast | 70 | 0.79 (0.62–1.00) | 227 | 0.89 (0.78–1.02) | 283 |
0.77 (0.68–0.87)
|
Cervix | 43 |
1.56 (1.13–2.11)
| 33 | 1.28 (0.88–1.80) | 26 | 1.32 (0.86–1.93) |
Endometrium | 11 | 1.21 (0.60–2.16) | 67 | 1.06 (0.82–1.35) | 99 | 1.07 (0.87–1.31) |
Ovary | 15 | 1.72 (0.96–2.83) | 26 | 1.09 (0.71–1.59) | 31 | 0.93 (0.63–1.31) |
Prostate | 15 |
1.10 (0.62–1.81)
| 326 |
0.66 (0.59–0.74)
| 776 |
0.68 (0.63–0.73)
|
Bladder | 15 | 1.65 (0.93–2.73) | 126 |
1.41 (1.18–1.68)
| 220 | 1.07 (0.93–1.22) |
Kidney | 21 | 1.54 (0.96–2.36) | 106 |
1.35 (1.10–1.63)
| 119 | 1.12 (0.93–1.34) |
Thyroid gland | 23 | 1.05 (0.66–1.57) | 53 |
1.49 (1.12–1.95)
| 43 | 1.37 (0.99–1.84) |
NHL high/low | 10 | 1.24 (0.59–2.27) | 45 | 1.29 (0.94–1.73) | 56 | 1.15 (0.87–1.50) |
CLL/ALL | 3 | 1.86 (0.38–5.44) | 14 | 0.71 (0.39–1.19) | 39 | 1.11 (0.79–1.52) |
All cancers combined | 447 |
1.24 (1.12–1.36)
| 1784 | 1.02 (0.97–1.07) | 2718 |
0.85 (0.82–0.89)
|